Overprescribing Psychiatric Drugs to Youth

Across the United States and other developed countries, the rate of psychiatric drug prescribing to children and adolescents has soared to levels that defy both medical necessity and ethical justification. Surveys reveal that 8.5 percent of American youth under 18 are on at least one psychiatric drug, including stimulants, antidepressants, and antipsychotics. These substances are often prescribed in combinations, despite little understanding of their cumulative effects on developing brains. Even toddlers as young as two are being medicated off-label with powerful antipsychotics—drugs originally designed for adult psychosis—without adequate scientific evidence of safety or benefit.

In nations such as Australia and the United Kingdom, similar trends are emerging. The use of antidepressants and stimulants among minors has risen sharply, suggesting a systemic expansion of psychiatry into childhood behavior and education. The claim that such prescribing reflects improved access to care collapses under scrutiny; the biological models underpinning these practices remain unproven, and the long-term harms of polypharmacy in children are scarcely studied. Organizations including the Council for Evidence-based Psychiatry, the International Institute for Psychiatric Drug Withdrawal, A Disorder 4 Everyone, and Mad in America have warned that this epidemic of drugging is driven more by commercial interests and institutional complacency than by genuine clinical science.

The mass medicalization of childhood through psychiatric drugs reveals a crisis of accountability within modern psychiatry. By pathologizing ordinary distress and behavioral diversity, the industry risks sacrificing an entire generation’s well-being to pharmaceutical dependency and profit.